Absolute mush. Big players know nothing that we don't know at this point. It will all be played out on Thursday when discussion ends and the votes are counted.
Disclosure--Long 10,000 shares. I've ridden FDA Panel out before on Amyln (AMLN) and Allos (ALTH)...both fast-tracked but adjudged only "approvable" first time through. Took a hit, but eventually I made d*#% good money on both. Ditto with Elan when it applied to return its MS drug Tysabri to market. That time, the FDA panel vote went Elan's way...barely. Stock jumped $3/share within first 15 minutes of the panel vote--as the shorts scrambled to cover.